Quoin Pharmaceuticals, Ltd.
QNRX
$5.91
-$0.16-2.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.06% | 20.05% | 12.45% | 0.64% | -2.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.95% | 59.02% | 77.49% | 60.97% | 8.45% |
| Operating Income | -87.95% | -59.02% | -77.49% | -60.97% | -8.45% |
| Income Before Tax | -88.14% | -68.02% | -87.23% | -63.80% | -12.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -88.14% | -68.02% | -87.23% | -63.80% | -12.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.14% | -68.02% | -87.23% | -63.80% | -12.75% |
| EBIT | -87.95% | -59.02% | -77.49% | -60.97% | -8.45% |
| EBITDA | -88.87% | -59.60% | -78.41% | -61.60% | -8.58% |
| EPS Basic | 86.57% | 58.79% | 54.07% | 83.21% | 82.14% |
| Normalized Basic EPS | 86.57% | 58.79% | 54.07% | 83.21% | 82.14% |
| EPS Diluted | 86.57% | 59.15% | 53.95% | 83.21% | 82.14% |
| Normalized Diluted EPS | 86.57% | 58.79% | 54.07% | 83.21% | 82.14% |
| Average Basic Shares Outstanding | 1,300.51% | 307.62% | 307.62% | 875.54% | 531.56% |
| Average Diluted Shares Outstanding | 1,324.00% | 309.76% | 309.76% | 882.35% | 525.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |